In front of the successive development of an HTLV-I seroconversion and a neuromyelopathy in a French Caucasian following a cardiac transplantation, an ascendant epidemiologic investigation must be manage to search a risk factor or a possible blood donor contaminated with HTLV-I virus. We selected an HTLV-I seropositive donor whose RBC participated to the patient's transfusion. This woman from Martinique island was a regular donor in our blood center and a second investigation was initiated to examine the patients transfused with the blood products issued from her previous donation. Nine were identified and controlled among them a patient who has received a RBC was found HTLV-I seropositive. An evaluation of the infectivity of the different blood products according to their type and specificity has been done. These data confirm that transmission of the HTLV-I is possible through donation of healthy seropositive donor and can induce the development of associated pathology, and prove the importance of screening blood donors for HTLV-I antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1140-4639(05)80065-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purification Method of Extracellular Vesicles Derived from Human T-Cell Leukemia Virus Type 1-Infected Cells without Virions.
Viruses
February 2024
Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki, Kihara 5200, Kiyotake, Miyazaki 889-1692, Japan.
To mediate intercellular communication, cells produce extracellular vesicles (EVs). These EVs transport many biomolecules such as proteins, nucleic acids, and lipids between cells and regulate pathophysiological actions in the recipient cell. However, EVs and virus particles produced from virus-infected cells are of similar size and specific gravity; therefore, the separation and purification of these two particles is often controversial.
View Article and Find Full Text PDFA role for an HTLV-1 vaccine?
Front Immunol
September 2022
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, United States.
HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of infected individuals develop myelopathy, lymphoproliferative malignancy, or inflammatory disorders, infection is associated with immunosuppression and shorter survival. Transmission of HTLV-1 is through contaminated blood or needles, mother-to-child exposure through breast-feeding, and sexual intercourse.
View Article and Find Full Text PDFEpidemiological Evidence of Nosocomial and Zoonotic Transmission of Human T-Cell Leukemia Virus-1 in a Large Survey in a Rural Population of Central Africa.
J Infect Dis
March 2023
Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, Université de Paris Cité, CNRS UMR 3569, Paris, France.
Article Synopsis
- - Central Africa, particularly Cameroon, has a high prevalence of HTLV-1, yet no preventive measures are in place to combat its transmission, which can occur through various means such as sexual contact, mother-to-child, and contaminated blood products.
- - A study conducted from 2019 to 2021 found that out of 3,400 participants, the HTLV-1 infection rate was 1.1%, with higher risks associated with factors like Pygmy ethnicity, a history of surgery, and bites from nonhuman primates.
- - The findings indicate both iatrogenic (from healthcare practices) and zoonotic (from animals) transmission of HTLV-1, highlighting the need for further research to develop public health
RAISING is a high-performance method for identifying random transgene integration sites.
Commun Biol
June 2022
Department of Virology II, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
Both natural viral infections and therapeutic interventions using viral vectors pose significant risks of malignant transformation. Monitoring for clonal expansion of infected cells is important for detecting cancer. Here we developed a novel method of tracking clonality via the detection of transgene integration sites.
View Article and Find Full Text PDFA novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
PLoS Negl Trop Dis
November 2021
InfYnity Biomarkers, Lyon, France.
Background: Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counselling of infected persons and avoid secondary transmission. Although high quality antibody screening assays are available, currently available confirmatory tests are costly and have variable performance, with high rates of indeterminate and non-typable results reported in many regions of the world.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!